In the Pipeline's Derek Lowe reminds his readers that interesting Phase II results don't always translate into successful Phase III tests. He points to Antisoma's AS404 and GenVec's TNFerade as examples. Both companies announced that their Phase III trials were being halted after it became clear that neither was going to meet its endpoints.